Mylan’s Acquisition of Global Marketing Rights to Once-Monthly Glatiramer Acetate Product through an Investment in and Partnership with Mapi Pharma

Cravath is representing Mylan in connection with the transaction. Mylan N.V. (“Mylan”), a global pharmaceutical company, and Mapi Pharma Ltd. (“Mapi Pharma”), a fully integrated, clinical…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now